Transparency Market Research (TMR) has published a new report titled, Viral Vector & Plasmid DNA Manufacturing Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192027. According to the report, theglobal viral vector & plasmid DNA manufacturing marketis expected to exceed a value of US$ 400 Mn by the end of 2019. The global market is anticipated to surpass US$ 2 Bn by 2027 and expand at a high double digit CAGR from 2019 to 2027. Rise in prevalence of cancer, genetic disorders, and increase in number of clinical studies are expected to augment the global market from 2019 to 2027. The viral vector & plasmid DNA manufacturing market is projected to expand owing to an increase in the awareness regarding viral vector based treatments and technological advancements in developing countries.

Increasing prevalence of cancer, genetic diseases, and infectious diseases

According to Cancer Research UK, there were 17 million new cases of cancer in 2018 and four most common types of cancer worldwide were breast, lung, bowel, and prostate cancers, which account for approximately 43% of all new cases. According to WHO estimates, currently, 10,000 of human diseases are known to be monogenic, caused by modifications in a single gene in human DNA. The global prevalence of all single gene diseases at birth is approximately 10/1000. In Canada, it is estimated that monogenic diseases may account for approximately 40% of the work of hospital-based pediatric practice. Increased prevalence of such disorders demands improved treatments, which in turn is anticipated to propel the viral vector & plasmid DNA manufacturing market during the forecast period.

Request a Sample of Viral Vector and Plasmid DNA Manufacturing Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30428

Increase in awareness regarding gene therapy

Awareness regarding gene therapy is increasing worldwide, as compared to the last few decades. According to an article published by Human Gene Therapy, the acceptance of gene therapy for severe disorders, such as Alzheimer Disease, is high as compared to less severe disease, such as attention deficit hyperactivity disorder. Furthermore, acceptability of gene therapy is increasing, and there is a strong need to provide the public and patients with up-to-date information. Moreover, opportunities to engage in the discourse about areas of research in gene therapy is a priority. This is estimated to propel the viral vector & plasmid DNA manufacturing market during the forecast period.

Cancer segment dominates the global market due to large number of clinical trials ongoing worldwide

In terms of disease, the cancer segment dominated the global viral vector & plasmid DNA manufacturing market, followed by genetic disorders. The segment accounted for a prominent market share, due to availability of approved viral vector-based cancer drugs and several ongoing clinical trials for the treatment of a variety of cancers. This creates lucrative opportunity for entry into the viral vector & plasmid DNA manufacturing market.

Plasmid DNA segment dominates the global market due to wide use in the manufacturing of viral vectors as well as DNA based vaccines

In terms of type, plasmid DNA is a highly attractive segment of the global viral vector & plasmid DNA manufacturing market, followed by the adeno-associated virus (AAV) segment. This is attributable to the extensive utilization of plasmid DNA as raw material in the manufacturing of various viral vectors.Furthermore, several studies have emphasized the benefits of DNA- based vaccines over conventional vaccines. The adeno-associated virus (AAV) segment is anticipated to expand at a considerable CAGR during the forecast period, due to several advantages offered by AAV over other vectors, making them the vector of choice for various clinical trials.

Request for a Discount on Viral Vector and Plasmid DNA Manufacturing Market Report -.

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=30428

North America dominates the global market owing to high acceptance of viral vector based treatments in the region

North America dominates the global viral vector & plasmid DNA manufacturing market due to a large patient pool, technological advancements, and high acceptance of advanced treatments in the region. The region is estimated to maintain its dominance during the forecast period. Moreover, rising healthcare expenditure, availability of approved gene therapy treatments, and increasing investments are key factors that are anticipated to boost the viral vector & plasmid DNA manufacturing market in the next few years. The viral vector & plasmid DNA manufacturing market in Asia Pacific is projected to expand at a notable CAGR due to increasing awareness regarding viral vector based products in developing countries and rising research initiatives in countries such as Japan and China.

Investments by key players is driving the globalviral vector & plasmid DNA manufacturing market

Major players operating in the viral vector & plasmid DNA manufacturing market include CobraBiologics, Novasep Inc., Cell and Gene Therapy Catapult, Kaneka Eurogentec S.A., FUJIFILM Diosynth Biotechnologies Inc., Spark Therapeutics, Inc. Merck KGaA, uniQure N.V., and Lonza.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel:+1-518-618-1030USA Canada Toll Free:866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.com

Continue reading here:
Viral Vector and Plasmid DNA Manufacturing Market is Estimated to Expand at a Robust CAGR by 2027 - Testifyandrecap

Comments are closed.